Immune checkpoint inhibitor sensitivity of DNA repair deficient tumors

• Published in: Immunotherapy Vol. 13; no. 14; pp. 1205 - 1213
• Main Authors: Rochefort, Pauline, Desseigne, Françoise, Bonadona, Valérie, Dussart, Sophie, Coutzac, Clélia, Sarabi, Matthieu, la Fouchardiere, Christelle de
• Format: Journal Article
• Language: English
• Published: England Future Medicine Ltd 01-10-2021
• Subjects: biomarker; BRCA; cancer; DNA repair deficiency; DNA Repair-Deficiency Disorders - complications; DNA Repair-Deficiency Disorders - drug therapy; Humans; immune checkpoint inhibitors; Immune Checkpoint Inhibitors - therapeutic use; immunotherapy; microsatellite instability; Neoplasms - drug therapy; Neoplasms - genetics; BRCA; microsatellite instability; DNA repair deficiency; immunotherapy; cancer; immune checkpoint inhibitors; biomarker
• ISSN: 1750-743X; 1750-7448
• DOI: 10.2217/imt-2021-0024

Faithful DNA replication is necessary to maintain genome stability and implicates a complex network with several pathways depending on DNA damage type: homologous repair, nonhomologous end joining, base excision repair, nucleotide excision repair and mismatch repair. Alteration in components of DNA repair machinery led to DNA damage accumulation and potentially carcinogenesis. Preclinical data suggest sensitivity to immune checkpoint inhibitors in tumors with DNA repair deficiency. Here, we review clinical studies that explored the use of immune checkpoint inhibitor in patient harboring tumor with DNA repair deficiency.